Table 1

patient characteristics

Patient nr	Gender	Age	Prior treatments	Metastatic sites	Location for tumor resection	Performance status
1	M	67	DTIC, ipilimumab	Lung, adrenal, subcutaneous	Subcutaneous	0
2	M	68	DTIC, DC vaccination, ipilimumab	Lung, LN, spleen, subcutaneous	LN	0
3	M	46	Vemurafenib, ipilimumab	LN, subcutaneous	Subcutaneous	0
4	F	44	DTIC, vemurafenib, ipilimumab	LN, subcutaneous, soft tissue	Subcutaneous	0
5	F	40	DTIC, ipilimumab	Lung, subcutaneous, soft tissue	Subcutaneous	0
6	F	43	Temozolamide, IFN-α, DC vaccination,	LN, long, subcutaneous	Axillary LN	0
			Ipilimumab, vemurafenib
7	M	52	DTIC, ipilimumab	LN, lung, subcutaneous	LN	0
8	M	40	Peptide vaccination, ipilimumab	LN, small intestine	Large intestine	0
					Mesoduodenum
9	F	60	Vemurafenib, DTIC, ipilimumab	LN, subcutaneous	LN	1
10	M	55	DC vaccination, ipilimumab	LN, subcutaneous, liver, lung	Jejunum	1